Medical Device News Magazine

VersaWrap Nerve Protector Receives 510(k) Clearance Reports Alafair Biosciences

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

September 24, 2020

The VersaWrap nerve protector received 510(k) clearance from the FDA. Alafair Biosciences announced the news today. Similar to VersaWrap® Tendon Protector indicated for tendon.

VersaWrap Nerve Protector is an ultrathin, sutureless, bioresorbable hydrogel implant ideally suited for covering and protecting peripheral nerves. By forming a permeable, gelatinous layer on or around the peripheral nerve, VersaWrap® provides a non-constricting interface between nerve and surrounding tissues during healing.

“VersaWrap is an exciting new product. We’ve been searching for something like this, a device that is pliable, that improves gliding, and that bioresorbs, to address adhesions,” stated Dr. Harvey Chim, MD, a plastic surgeon in Gainesville, FL. “Given the presence of hyaluronic acid in VersaWrap, the technology and its mechanism of action in tendon and peripheral nerve procedures makes sense. I’ve seen it work well in a variety of cases where scarring was a concern.” Dr. Chim has been using VersaWrap Tendon Protector for several years. “I use VersaWrap because my patients have better clinical outcomes.”

“We are pleased to have received 510(k) clearance for VersaWrap and believe that we will see rapid surgeon adoption given the unique characteristics of our product,” said Greg Brophy, CEO of Alafair. “Our patented hydrogel technology has diverse applications in the medical device and regenerative medicine segments, and the extension of our product portfolio to include peripheral nerve procedures is a substantial milestone for our organization.”

VersaWrap® is the second product in the VersaWrap® family of products to receive 510(k) clearance and is indicated for the management of peripheral nerve injuries in which there has been no substantial loss of nerve tissue. Alafair anticipates additional 510(k) filings as it seeks to expand the clinical applications for the use of its hydrogel technology.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”